Epigenetics implicated in clinical anti cancer resistance
Mar 20, 2006 cancer, research articles
A research team with the Centre of Oncology and Applied Pharmacology at Glasgow University postulate an epigenetic mechanism in driving polygenic resistance in cancer patients. The UK group suggests that the current focus of “specific genes or biochemical pathways” for acquired resistance to anti cancer drugs is an “oversimplification.” Rather, aberrant methylation of multiple genes occuring simultaneously during tumor development may be the key to cancer resistance. www.nature.com
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
